HOWL
Werewolf Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Werewolf Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Werewolf Therapeutics has 4 disclosed suppliers and 1 disclosed customer in SEC filings.
SentenceWe have an exclusive option under our November 2022 collaboration agreement with Adimab LLC to acquire ownership of a patent family directed to our IL-18 INDUKINE molecules and our WTX-518 product candidate.
HOWL 10-Kaccession 0001785530-26-000006
SentenceWe have licensed from Harpoon certain patents that are directed to single immunoglobulin variable domains that bind human serum albumin.
HOWL 10-Kaccession 0001785530-26-000006
SentenceIn March 2018, we entered into an assignment and license agreement, or the Harpoon Agreement, with Harpoon, pursuant to which we assigned to Harpoon certain patents related to adoptive cell therapies and binding moieties for conditional activation of immunoglobulin and non-immunoglobulin molecules, and Harpoon assigned to us certain patents related to certain inducible polypeptides and a binding moiety for conditional activation of certain polypeptides.
HOWL 10-Kaccession 0001785530-26-000006
SentenceWe have engaged Piper Sandler & Co, or Piper Sandler, to serve as exclusive financial advisor to assist in the strategic review process.
HOWL 10-Kaccession 0001785530-26-000006
SentenceFor example, in April 2022, we entered into a Collaboration and License Agreement, or the Collaboration Agreement, with Jazz Pharmaceuticals Ireland Limited, or Jazz, pursuant to which we granted Jazz certain licenses to develop and commercialize products containing our Interferon alpha, or IFNα, INDUKINE molecule, JZP898, as well as products containing certain isolated recombinant polypeptides comprising IFNα that meet specified criteria.
HOWL 10-Kaccession 0001785530-26-000006
Werewolf Therapeutics, Inc.
0.99
Largest filed tie
—
Expected move
Inputsspot 0.99exp Nov 20ATM strike 1ATM straddle 0.38IV 199%